A whistleblower lawsuit alleges that McKesson Corp. had been repackaging cancer drugs and charging the federal and state governments for “overfill,” extra drug that is routinely put into vials by manufacturers.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
